| Malignant ascites are a fluid based compound within the peritoneal cavity consisting of different proteins and tumor cells, mesothelial cells, fibroblasts, macrophages, leucocytes and cell detritus, whereby no clear definition of the different parameters and their concentration appears to exist. It is very imorportance to stuy the continuous hyperthermic intraperitoneal perfusion chemotherapy to treat gastric carcinoma and malignant ascites.Material and Method:1. Patients and controls choose 8 patients: From October 2008 to March 2009, the gastric cancer patients with malignant ascites who see the doctor in the Affiliated Tumor Hospital of Guangzhou Medical College.2. The SELDI-TOF-MS examination,use the standard protein chips of the All-in-one as to outer quod vide.3. The statistics analysi1) Analyze P value of the same protein peak value expressed in the serum in patints before and after treatment by CHIPC with Protein Chip Software 3.2 and Biomarker Wizard (BMW) software; Also, analyze P value of the same protein peak value expressed in the ascites in patints before and after treatment by CHIPC . according to the size of P value ,compare significant differences of mass to charge ratio of each peak in the two samples expression level, the smaller P value is ,the meaningful on the distinction between two types of samples is.2) Serum group, t test was used to compare the peak intensity before and after the perfusion, P﹤0.05 it is statistically significant difference.3) Ascites group, t test was used to compare the peak intensity before and after the perfusion, P﹤0.05 it is statistically significant difference.4) According to the detected differences in protein expression of both groups, we can directly from m/z differences in protein retrieval to complete by the database of University of Pittsburgh Department of Biomedical Informatics who has been set up proteomics experiments (EPO-KB), Analysis significance of the target protein related to the treatment of malignant ascites by CHIPC.Results:1) 83 effective protein peak were found By SELDI-TOF-MS detection in serum group; 74 effective protein peak were found By SELDI-TOF-MS detection in ascites group.2) There are certain overlaps in serum and ascites by SELDI-TOF-MS detection.3) Malignant ascites patients treated by CHIPC serum group, 8 cases before perfusion VS 8 cases after perfusion, 22 P﹤0.05different proteins were found.4) Malignant ascites patients treated by CHIPC ascites group, 8 cases before perfusion VS 8 cases after perfusion, 20 P﹤0.05different proteins were found.5) Serum and ascites group, there are following different expressed proteins both highly expressed in the two groups before and after perfusion, m/z values are: 5582.36Da,3448.56Da,4418.04Da,7767.61Da,11661.53Da,3378.49Da和8604.72Da。6) Experiments in proteomics database (EPO-KB) retrieve the difference in molecular weight protein detected m/z value 7767.61Da target protein platelet factor 4 (PF4), the other six protein could not be found to coincide with the target proteins. Conclusions:1) SELDI-TOF-MS technology is an effective tool in screening and prediction for specific proteins at malignant ascites by treatment of CHIPC.2) Malignant ascites by treatment of CHIPC ,the protein expression differences were both significant in two groups3) Malignant ascites by treatment of CHIPC ,some overlaps in protein peak show the correlation between the two groups。4) M/z value 5582.36Da,3448.56Da,4418.04Da,7767.61Da,11661.53Da,3378.49Da and 8604.72Da 7 protein peaks were both highly expressed in serum and ascites group.5) We Obtained target protein platelet factor 4 (PF4) by searching m/z value 7767.61Da ,the other six protein could not be found to coincide with the target proteins. |
PDF Full Text Request